Therapeutic targets of triple-negative breast cancer: A review

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4228-4237

  Jamdade, Vinayak S ^a   Sethi, Nikunj ^b,c   Mundhe, Nitin A ^a   Kumar, Parveen ^a   Lahkar, Mangala ^a,d   Sinha, Neeraj ^b,c  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d GAUHATI MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CSPG4 SPECIFIC MONOCLONAL ANTIBODY; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GALUNISERTIB; GEFITINIB; GEMCITABINE; INIPARIB; IXABEPILONE; LAPATINIB; MONOCLONAL ANTIBODY; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NERATINIB; NOTCH RECEPTOR; OLAPARIB; PANITUMUMAB; RUCAPARIB; SALINOMYCIN; SONIC HEDGEHOG PROTEIN; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VELIPARIB; WNT PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ARTICLE; BETA CATENIN SIGNALLING PATHWAY; HEDGEHOG SIGNALLING PATHWAY; HUMAN; NOTCH SIGNALLING PATHWAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WNT SIGNALING PATHWAY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TRENDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84938748194     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13211     Document Type: Article

References (72)

1. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS, (2011). Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 10: 9-15.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
5. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB, (1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258: 7155-7160.
6. Bai CB, Stephen D, Joyner AL, (2004). All mouse ventral spinal cord patterning by hedgehog is Gli dependent and involves an activator function of Gli3. Dev Cell 6: 103-115.
7. Barker N, Clevers H, (2006). Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014.
8. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, etal. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14.
9. Beevers CS, Li F, Liu L, Huang S, (2006). Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119: 757-764.
10. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, etal. (2013). TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123: 1348-1358.
11. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, etal. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
12. Campoli M, Ferrone S, Wang X, (2010). Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109: 73-121.
13. Cattaruzza S, Nicolosi PA, Braghetta P, Pazzaglia L, Benassi MS, Picci P, etal. (2013). NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. J Mol Cell Biol 5: 176-193.
14. Cayuso J, Ulloa F, Cox B, Briscoe J, Marti E, (2006). The Sonic hedgehog pathway independently controls the patterning, proliferation and survival of neuroepithelial cells by regulating Gli activity. Development 133: 517-528.
15. Chacon RD, Costanzo MV, (2010). Triple-negative breast cancer. Breast Cancer Res 12 (Suppl 2): S3.
16. Curigliano G, Goldhirsch A, (2011). The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr 2011: 108-110.
17. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, etal. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
18. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, etal. (2013). Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 110: 1815-1820.
19. Gauthier ML, Torretto C, Ly J, Francescutti V, O'Day DH, (2003). Protein kinase C alpha negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor. Biochem Biophys Res Commun 307: 839-846.
20. Ghadami M, Makita Y, Yoshida K, Nishimura G, Fukushima Y, Wakui K, etal. (2000). Genetic mapping of the Camurati-Engelmann disease locus to chromosome 19q13.1-q13.3. Am J Hum Genet 66: 143-147.
21. Gilbert KM, Thoman M, Bauche K, Pham T, Weigle WO, (1997). Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in naive T cells. Immunol Invest 26: 459-472.
22. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N, (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-1927.
23. Godon C, Cordelieres FP, Biard D, Giocanti N, Megnin-Chanet F, Hall J, etal. (2008). PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 36: 4454-4464.
24. Hay N, Sonenberg N, (2004). Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
25. Herbst RS, (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2 Suppl): 21-26.
26. Ismail-Khan R, Bui MM, (2008). A review of triple-negative breast cancer. Cancer Control 17: 173-176.
27. Jiang J, Hui CC, (2008). Hedgehog signaling in development and cancer. Dev Cell 15: 801-812.
28. Kasper M, Regl G, Frischauf AM, Aberger F, (2006). GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 42: 437-445.
29. Kasper M, Jaks V, Fiaschi M, Toftgard R, (2009). Hedgehog signalling in breast cancer. Carcinogenesis 30: 903-911.
30. Katoh Y, Katoh M, (2008). Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 22: 271-275.
31. King TD, Suto MJ, Li Y, (2012). The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 113: 13-18.
32. Kogerman P, Grimm T, Kogerman L, Krause D, Unden AB, Sandstedt B, etal. (1999). Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol 1: 312-319.
33. Kumar P, Bolshette NB, Jamdade VS, Mundhe NA, Thakur KK, Saikia KK, etal. (2013). Breast cancer status in India: an overview. Biomed Prev Nutr 3: 177-183.
34. Letterio JJ, Roberts AB, (1998). Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161.
35. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA, (2011a). Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A 108: 13253-13257.
36. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y, (2011b). Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS ONE 6: e29290.
37. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, etal. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
38. Merchant AA, Matsui W, (2010). Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 16: 3130-3140.
39. Moore PA, Rosen CA, Carter KC, (1996). Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization. Genomics 33: 331-332.
40. Naujokat C, Steinhart R, (2012). Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012: 950658.
41. Olsauskas-Kuprys R, Zlobin A, Osipo C, (2013). Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 6: 943-955.
42. Oro AE, (2007). The primary cilia, a 'Rab-id' transit system for hedgehog signaling. Curr Opin Cell Biol 19: 691-696.
43. Otvos L Jr, Surmacz E, (2011). Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev Anticancer Ther 11: 1147-1150.
44. Palma V, Ruiz i Altaba A, (2004). Hedgehog-GLI signaling regulates the behavior of cells with stem cell properties in the developing neocortex. Development 131: 337-345.
45. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
46. Penault-Llorca F, Viale G, (2012). Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol 23 (Suppl 6): vi19-vi22.
47. Polkinghorn WR, Tarbell NJ, (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4: 295-304.
48. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, etal. (2005). High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537.
49. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC, (2011). Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137: 183-192.
50. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J, (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
51. Schuller U, Zhao Q, Godinho SA, Heine VM, Medema RH, Pellman D, etal. (2007). Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors. Mol Cell Biol 27: 8259-8270.
52. Schultz N, Lopez E, Saleh-Gohari N, Helleday T, (2003). Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31: 4959-4964.
53. Shih M, Wang TL, (2007). Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67: 1879-1882.
54. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, etal. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
55. Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, etal. (2012). Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol 20: 139-145.
56. Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A, etal. (2005). The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol 1: 2005.0022.
57. Taipale J, Cooper MK, Maiti T, Beachy PA, (2002). Patched acts catalytically to suppress the activity of Smoothened. Nature 418: 892-897.
58. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG, (2002). FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773-4780.
59. Tiemessen MM, Kunzmann S, Schmidt-Weber CB, Garssen J, Bruijnzeel-Koomen CA, Knol EF, etal. (2003). Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol 15: 1495-1504.
60. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, etal. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376: 235-244.
61. Ueno NT, Zhang D, (2011). Targeting EGFR in triple negative breast cancer. J Cancer 2: 324-328.
62. Vaughn SP, Broussard S, Hall CR, Scott A, Blanton SH, Milunsky JM, etal. (2000). Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region. Genomics 66: 119-121.
63. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW, (2004). Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 23: 7322-7329.
64. Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, etal. (1988). Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140: 3026-3032.
65. Wahl SM, Wen J, Moutsopoulos N, (2006). TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 213: 213-227.
66. Waldman AS, Waldman BC, (1991). Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation). Nucleic Acids Res 19: 5943-5947.
67. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, etal. (2010a). CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102: 1496-1512.
68. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, etal. (2010b). CSPG4 in cancer: multiple roles. Curr Mol Med 10: 419-429.
69. Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, etal. (2011). Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 71: 7410-7422.
70. Wismar J, Habtemichael N, Warren JT, Dai JD, Gilbert LI, Gateff E, (2000). The mutation without children(rgl) causes ecdysteroid deficiency in third-instar larvae of Drosophila melanogaster. Dev Biol 226: 1-17.
71. Wullschleger S, Loewith R, Hall MN, (2006). TOR signaling in growth and metabolism. Cell 124: 471-484.
72. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, etal. (2007). ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058.